Northwire Canada EditionWednesday, July 15, 2026
Sign inSubscribe
Northwire
⌕
EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0% EFF 0.030 +20.0% W 0.500 +1.0% RDG 0.160 +0.0% ARIC 0.780 +4.0% VROY 3.44 +5.2% ROCK 3.81 +3.0% APMI 0.120 +0.0% EM 3.58 −4.8% ALS 66.04 +6.8% MEK 0.065 +44.4% TLO 6.00 +13.0% ADE 0.045 −66.7% FAIR 0.060 +33.3% SVRS 0.420 −2.3% RES 0.050 +42.9% CYG 0.120 +0.0%
Other

Aurora Cannabis brings Whistler Cannabis to Australia

By The Northwire Desk — AI Analysis Aug 12, 2025 · 13:50 ACB · 7.18 Aurora Cannabis Inc
ACB · Price

Executive Summary

  • Aurora Cannabis Inc. has officially launched its Whistler Cannabis Co. brand in Australia, marking a significant step in its global expansion strategy.
  • The launch introduces premium, indoor craft medical cannabis products to Australian patients, leveraging Aurora's Canadian cultivation expertise and proprietary genetics.
  • Two specific cultivars, Ginger Breath and Critical Diesel, are the initial products available, highlighting the company's focus on high-THC, terpene-rich medical cannabis.

Key Details

  • Brand Launch: Whistler Cannabis Co. is being introduced to the Australian market as one of Canada's original cannabis brands.
  • Product Specifications:
    • Ginger Breath: Indica, 32% THC, 10 grams. Genetics: '91 Royale and Driftwood Diesel. Terpene profile: caryophyllene, pinene, and linalool. Aroma: spicy ginger, gasoline, chai, and citrus.
    • Critical Diesel: Sativa, 28% THC, 10 grams. Genetics: Critical Sensi Star and Driftwood Diesel. Terpene profile: caryophyllene, pinene, and myrcene. Aroma: cherry, grape, strawberry, vanilla, and gasoline.
  • Production Origin: Products are cultivated at Aurora Alpine in the Pemberton Valley, British Columbia.
  • Cultivation Method: Small-batch production using top-tier proprietary genetics, harvested at peak maturity, hang dried, and hand trimmed to preserve trichomes.
  • Regulatory Compliance: Production adheres to European Union (EU) and Therapeutics Goods Administration (TGA) Good Manufacturing Practices (GMP) standards.
  • Strategic Context: The move underscores Aurora's commitment to global growth and its patient-first approach in international medical cannabis markets.

Notable Quotes

  • "Whistler is a tried-and-true brand in the Canadian market," said Andre Jerome, executive vice-president of global business development at Aurora. "We're excited to now extend its legacy and our Canadian cultivation expertise to Australian patients. This milestone underscores our commitment to global growth and our patient-first approach."
Read the original news release →

More from Aurora Cannabis Inc

Jun 11, 2026 · 07:05

Record FY2026 revenue masks structural margin contraction and explicit FY2027 guide-cut; cash-rich but capital allocation remains dilutive.

Earnings May 14, 2026 · 08:45

Aurora Cannabis Secures IP Rights Amidst Sector Consolidation and Price Stabilization

M&A / Property May 14, 2026 · 06:54

Aurora Secures IP Moat Amidst Dilution Concerns and Cash Burn

M&A / Property Apr 28, 2026 · 15:57

Aurora Cannabis Expands Global Medical Portfolio Amidst Dilution Concerns and Profitability Push

Production / Operations Apr 28, 2026 · 06:53

Product Expansion Validates EU Capacity Play, But Dilution Risk Looms Over Cash Burn

Production / Operations Apr 15, 2026 · 07:05

Aurora Cannabis Acquires EU GMP Capacity Amidst Stock Decline

M&A / Property